Investigating how a specific pathway contributes to blood vessel inflammation and heart disease
LysoPI/GPR55 pathway promotes endothelial activation, vascular inflammation and atherosclerosis
This study is looking at how a substance called lysoPI can cause inflammation in blood vessels, which might lead to heart disease, and the researchers hope to find new ways to reduce this inflammation and help people with atherosclerosis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Temple Univ of the Commonwealth NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11004025 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of lysophosphatidylinositol (lysoPI) in promoting inflammation in blood vessels, which can lead to atherosclerosis, a major cause of heart disease. The researchers will explore how lysoPI activates endothelial cells, which line blood vessels, and how this activation contributes to vascular inflammation. By studying the mechanisms involved, including the interaction with specific receptors and the generation of reactive oxygen species, the team aims to identify potential new anti-inflammatory therapies for atherosclerosis.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for atherosclerosis, including those with high cholesterol, obesity, or a family history of heart disease.
Not a fit: Patients who do not have risk factors for atherosclerosis or existing cardiovascular conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that reduce inflammation and prevent the progression of atherosclerosis, improving heart health.
How similar studies have performed: Previous research has shown promising results in targeting inflammatory pathways in cardiovascular diseases, suggesting that this approach may yield significant insights.
Where this research is happening
Philadelphia, United States
- Temple Univ of the Commonwealth — Philadelphia, United States (Active)
Researchers
- Principal investigator: Yang, Xiaofeng — Temple Univ of the Commonwealth
- Study coordinator: Yang, Xiaofeng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.